Prostate Cancer | Philip Kantoff, MD

published 5 months ago by Dr Neil Love

Prostate Cancer Update, Issue 1, 2021 — Part 2: Our interview with Dr Kantoff highlights the following topics as well as cases from his practice: Optimal management of metastatic CRPC (mCRPC);  promising agents and strategies under investigation — Presentation (0:00) Management of de novo metastatic prostate cancer; recommendations for screening and implications for clinical presentation (26:00) Benefit with the addition of chemotherapy or secondary hormonal therapy to ADT for patients with metastatic prostate cancer (31:22) Choice of androgen receptor inhibitor for patients with metastatic prostate cancer; impact of COVID-19 on therapeutic decision-making (37:00) Molecular profiling for patients with prostate cancer; spectrum of related genetic alterations (43:49) Activity of the AKT inhibitor ipatasertib in patients with mCRPC (49:22) Role of immune checkpoint inhibitors alone and in combination with targeted therapy for mCRPC (51:20) Efficacy and tolerability of radium-223 in patients with CRPC and bone metastases (56:36) Activity of PARP inhibitors in patients with mCRPC (1:02:00) CARD trial results: Improvement in overall survival with cabazitaxel versus enzalutamide or abiraterone for patients with mCRPC previously treated with docetaxel who experienced rapid disease progression on a prior androgen receptor-targeted agent (1:07:07) CME information and select publications

more episodes from Research To Practice | Oncology Videos